Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS

被引:28
|
作者
Berscheid, Anne [1 ]
Francois, Patrice [2 ,3 ]
Strittmatter, Axel [4 ]
Gottschalk, Gerhard [4 ]
Schrenzel, Jacques [2 ,3 ]
Sass, Peter [5 ]
Bierbaum, Gabriele [1 ]
机构
[1] Univ Bonn, IMMIP, Bonn, Germany
[2] Univ Hosp Geneva, Infect Dis Serv, Genom Res Lab, Geneva, Switzerland
[3] Univ Geneva, Geneva, Switzerland
[4] Univ Gottingen, Inst Microbiol & Genet, D-37073 Gottingen, Germany
[5] Univ Dusseldorf, Inst Pharmaceut Biol, Dusseldorf, Germany
关键词
glycopeptides; teicoplanin; daptomycin; antibiotic resistance; two-component regulatory systems; WALL STRESS STIMULON; CELL-WALL; DAPTOMYCIN SUSCEPTIBILITY; DECREASED SUSCEPTIBILITY; GLYCOPEPTIDE-RESISTANCE; REDUCED SUSCEPTIBILITY; 2-COMPONENT SYSTEM; MPRF; EXPRESSION; MECHANISMS;
D O I
10.1093/jac/dku297
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Staphylococcus aureus is a notorious bacterial pathogen and antibiotic-resistant isolates complicate current treatment strategies. We characterized S. aureus VC40, a laboratory mutant that shows full resistance to glycopeptides (vancomycin and teicoplanin MICs a parts per thousand yen32 mg/L) and daptomycin (MICaEuroS=aEuroS4 mg/L), to gain deeper insights into the underlying resistance mechanisms. Genomics and transcriptomics were performed to characterize changes that might contribute to development of resistance. The mutations in vraS were reconstituted into a closely related parental background. In addition, antimicrobial susceptibility testing, growth analyses, transmission electron microscopy, lysostaphin-induced lysis and autolysis assays were performed to characterize the phenotype of resistant strains. Genome sequencing of strain VC40 revealed 79 mutations in 75 gene loci including genes encoding the histidine kinases VraS and WalK that control cell envelope-related processes. Transcriptomics indicated the increased expression of their respective regulons. Although not reaching the measured MIC for VC40, reconstitution of the L114S and D242G exchanges in VraS(VC40) into the susceptible parental background (S. aureus NCTC 8325) resulted in increased resistance to glycopeptides and daptomycin. The expression of VraS(VC40) led to increased transcription of the cell wall stress stimulon, a thickened cell wall, a decreased growth rate, reduced autolytic activity and increased resistance to lysostaphin-induced lysis in the generated mutant. We show that a double mutation of a single gene locus, namely vraS, is sufficient to convert the vancomycin-susceptible strain S. aureus NCTC 8325 into a vancomycin-intermediate S. aureus.
引用
收藏
页码:3190 / 3198
页数:9
相关论文
共 50 条
  • [1] Heteroresistance in Vancomycin-Intermediate Staphylococcus aureus (VISA), susceptible or resistant?
    Labarca, Jaime
    REVISTA CHILENA DE INFECTOLOGIA, 2015, 32 (05): : 497 - 498
  • [2] Treatment of vancomycin-intermediate Staphylococcus aureus (VISA) endocarditis with linezolid
    Balkhair, Abdullah
    Al Muharrmi, Zakariya
    Darwish, Laila
    Farhan, Hatem
    Sallam, Mansour
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2010, 14 : E227 - E229
  • [3] Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
    Su, Michelle
    Davis, Michelle H.
    Peterson, Jessica
    Solis-Lemus, Claudia
    Satola, Sarah W.
    Read, Timothy D.
    PEERJ, 2021, 9
  • [4] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Jung Wan Park
    Hyungmin Lee
    Jung Wook Kim
    Bongyoung Kim
    Scientific Reports, 9
  • [5] Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
    Park, Jung Wan
    Lee, Hyungmin
    Kim, Jung Wook
    Kim, Bongyoung
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [6] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    Fong, R. K. C.
    Low, J.
    Koh, T. H.
    Kurup, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (08) : 983 - 987
  • [7] Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore
    R. K. C. Fong
    J. Low
    T. H. Koh
    A. Kurup
    European Journal of Clinical Microbiology & Infectious Diseases, 2009, 28
  • [8] Recognition and management of infections caused by vancomycin-intermediate Staphylococcus aureus (VISA) and heterogenous VISA (hVISA)
    Howden, BP
    INTERNAL MEDICINE JOURNAL, 2005, 35 : S136 - S140
  • [9] Vancomycin-intermediate resistance in Staphylococcus aureus
    Hiramatsu, Keiichi
    Kayayama, Yuki
    Matsuo, Miki
    Aiba, Yoshifumi
    Saito, Michie
    Hishinuma, Tomomi
    Iwamoto, Akira
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2014, 2 (04) : 213 - 224
  • [10] Vancomycin-intermediate Staphylococcus aureus in Korea
    Kim, MN
    Pai, CH
    Woo, JH
    Ryu, JS
    Hiramatsu, K
    JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (10) : 3879 - 3881